NCT04727008

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Status unknown Phase 1 Last updated 12 December 2023

What this trial tests

Phase 1 trial testing CXCR4 modified anti-BCMA CAR T cells in Multiple Myeloma in 12 participants. Status unknown.

Timeline

21 September 2022

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	21 September 2022
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

• CXCR4 modified anti-BCMA CAR T cells — full drug profile →

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Sichuan University

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a cell surface receptor that expressed primarily by malignant and normal plasma cells. This study aims to evaluate the safety and tolerance CXCR4 modified BCMA CAR T cells in treating standard treatment failed refractory/relapsed multiple myeloma, and will follow dose-escalating cohorts. The efficacy of CXCR4 modified BCMA CAR T will also be investigated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting cytokine and chemokine signaling pathways for cancer therapy.
   Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
2. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
   Guzman G, Reed MR, Bielamowicz K, Koss B, et al · · 2023 · cited 121× · PMID 36853475 · DOI 10.1007/s11912-023-01380-x
3. Role of chemokine systems in cancer and inflammatory diseases.
   Li H, Wu M, Zhao X. · · 2022 · cited 85× · PMID 35702353 · DOI 10.1002/mco2.147
4. Harnessing the chemokine system to home CAR-T cells into solid tumors.
   Foeng J, Comerford I, McColl SR. · · 2022 · cited 78× · PMID 35492880 · DOI 10.1016/j.xcrm.2022.100543
5. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
   Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
6. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
   Kilgour MK, Bastin DJ, Lee SH, Ardolino M, et al · · 2023 · cited 47× · PMID 37205115 · DOI 10.3389/fimmu.2023.1166038
7. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden.
   Biondi M, Tettamanti S, Galimberti S, Cerina B, et al · · 2023 · cited 42× · PMID 36787509 · DOI 10.1182/blood.2022018330
8. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
   Mishra AK, Gupta A, Dagar G, Das D, et al · · 2023 · cited 29× · PMID 38006053 · DOI 10.3390/vaccines11111721